We have located links that may give you full text access.
The down-regulation of long non-coding RNA LINC01088 is associated with the poor prognosis of epithelial ovarian cancer patients.
European Review for Medical and Pharmacological Sciences 2018 September
OBJECTIVE: Long intergenic non-coding RNA 1088 (LINC01088) has been suggested to act as a tumor suppressor in epithelial ovarian cancer (EOC); however, the prognostic role of LINC01088 has not been evaluated in cancer patients. This study aimed to investigate the expression of LINC01088 in EOC, along with evaluating its clinical-pathological and prognostic importance.
PATIENTS AND METHODS: A bioinformatics tool (GEPIA) was used to screen the dysregulated lncRNAs. Quantitative Real-time PCR (qRT-PCR) was used to measure expression level of LINC01088 in EOC tumor samples and adjacent non-tumor tissues. Then, the association between LINC01088 expression and pathological parameters were further evaluated. Overall survival (OS) was estimated using the Kaplan-Meier method, and the differences in survival were compared using the log-rank test. Univariate and multivariate analysis were performed using the Cox proportional hazard analysis.
RESULTS: We found that LINC01088 expression was significantly down-regulated in EOC tissues via "GEPIA". Then, the results of RT-PCT confirmed that the expression levels of LINC01088 were significantly lower in EOC tissues compared to adjacent noncancerous tissues (p < 0.01). Interestingly, lower LINC01088 expression levels were associated with FIGO stage (p = 0.000), grade (p = 0.003) and distant metastasis (p = 0.006). Moreover, Kaplan-Meier analysis indicated that patients with low LINC01088 expression had a poor overall survival (p = 0.0013). Finally, univariate and multivariate analysis show that LINC01088 expression is an independent predictor for overall survival.
CONCLUSIONS: Low LINC01088 expression was associated with the progression of EOC and could serve as a potential independent prognostic biomarker for patients with EOC.
PATIENTS AND METHODS: A bioinformatics tool (GEPIA) was used to screen the dysregulated lncRNAs. Quantitative Real-time PCR (qRT-PCR) was used to measure expression level of LINC01088 in EOC tumor samples and adjacent non-tumor tissues. Then, the association between LINC01088 expression and pathological parameters were further evaluated. Overall survival (OS) was estimated using the Kaplan-Meier method, and the differences in survival were compared using the log-rank test. Univariate and multivariate analysis were performed using the Cox proportional hazard analysis.
RESULTS: We found that LINC01088 expression was significantly down-regulated in EOC tissues via "GEPIA". Then, the results of RT-PCT confirmed that the expression levels of LINC01088 were significantly lower in EOC tissues compared to adjacent noncancerous tissues (p < 0.01). Interestingly, lower LINC01088 expression levels were associated with FIGO stage (p = 0.000), grade (p = 0.003) and distant metastasis (p = 0.006). Moreover, Kaplan-Meier analysis indicated that patients with low LINC01088 expression had a poor overall survival (p = 0.0013). Finally, univariate and multivariate analysis show that LINC01088 expression is an independent predictor for overall survival.
CONCLUSIONS: Low LINC01088 expression was associated with the progression of EOC and could serve as a potential independent prognostic biomarker for patients with EOC.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
The Effect of Albumin Administration in Critically Ill Patients: A Retrospective Single-Center Analysis.Critical Care Medicine 2024 Februrary 8
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app